2 products of ‘Amosartan,’ Hanmi’s modified medicines,’ record highest annual manufacturing performance with KRW 57.5 billion

Published: 2017-07-11 16:27:00
Updated: 2017-07-11 11:15:09

There were 9 products making more than KRW 10 billion last year out of pharmaceutical products approved as incrementally modified drug, and 2 products of Amosartan, Hanmi Pharm’s antihypertensives, recorded the highest with KRW 57.5 billion in production.

According to the Ministry of Food and Dr...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.